Reynolds Angela A

Previous page
1 / 2
You're on page 1
page 2
Next page

Sort by:

Relevance

Page size

Reynolds2006 - Reduced model of the acute inflammatory response

Angela Reynolds, Jonathan Rubin, Gilles Clermont, Judy Day, Yoram Vodovotz & G. Bard Ermentrout. A reduced mathematical model of the acute inflammatory response: I. Derivation of model and analysis of anti-inflammation. Journal of Theoretical Biology 242, 1 (2006). The acute inflammatory response, ...

2024-09-02 | BIOMD0000000714 | BioModels

Transcription profiling of human HeLa cells treated with various functional siRNAs to investigate RNAi off-targets

Human HeLa cells were treated with various functional siRNAs of different sequence targeting several genes (100 nM or 50 nM for 24 hours). There are two transfection groups - in the first, containing biological duplicates (A and B), the mock-transfected control samples are pooled as a Cy3 reference...

ORGANISM(S): Homo sapiens

2006-03-01 | E-MEXP-668 | biostudies-arrayexpress

Cooper2015 - Modeling the effects of systemic mediators on the inflammatory phase of wound healing

This is an ordinary differential equation-based mathematical model describing the inflammatory phase of the wound healing response. The model describes the interactions in the wound between wound debris, pathogens, neutrophils and macrophages, as well as the modulation of these interactions by estro...

2024-09-02 | BIOMD0000000855 | BioModels

RNAi knock down of endogenous genes and luciferase reporters in human HeLa cells to examine the effect of seed complement frequency on off-target signatures

siRNAs were designed against both endogenous genes and luciferase reporters to examine the effect of seed complement frequency on off-target signatures as measured by Agilent Human 1A gene expression analysis.

ORGANISM(S): Homo sapiens

2008-03-15 | E-MEXP-1402 | biostudies-arrayexpress

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Not available

S-EPMC8598213 | biostudies-literature

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Not available

S-EPMC8084355 | biostudies-literature

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Not available

S-EPMC10957483 | biostudies-literature

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.